Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206050 · ClinicalTrials.gov registry record · Phase 4
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
A Phase 4 study of Healthy, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00206050 is a Phase 4 study of Healthy that has completed, run by AstraZeneca. The registered enrollment target is 40 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00206050, a Phase 4 study of Healthy, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection).
Conditions Studied
Interventions
- DRUG Esomeprazole
- DRUG pantoprazole
Study Locations (1)
Oklahoma
- Research Site - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-09 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206050
The ClinicalTrials.gov registry entry for NCT00206050 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Esomeprazole is the first listed.
NCT00206050 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00206050 about?
NCT00206050 is a clinical study titled "Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po". This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) ...
What is the current status of trial NCT00206050?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2004-09. Estimated completion is 2004-12.
What conditions does trial NCT00206050 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00206050?
The interventions under investigation include: Esomeprazole (DRUG), pantoprazole (DRUG).
Who is sponsoring clinical trial NCT00206050?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00206050 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
-
Pharmacokinetics of Transdermal Metronidazole
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.